William Blair Has Strong Estimate for ZVRA FY2025 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at William Blair increased their FY2025 EPS estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, November 5th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of $0.08 for the year, up from their previous forecast of ($0.03). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics’ Q4 2025 earnings at $0.07 EPS, Q1 2026 earnings at $0.12 EPS, Q2 2026 earnings at $0.15 EPS and FY2026 earnings at $0.67 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $26.06 million for the quarter, compared to analyst estimates of $26.64 million. Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%.

Other equities analysts also recently issued research reports about the stock. JMP Securities decreased their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a report on Wednesday, August 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Tuesday, October 14th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Cantor Fitzgerald lowered their target price on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Finally, Zacks Research cut Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.80.

Zevra Therapeutics Trading Up 3.6%

NASDAQ:ZVRA opened at $9.43 on Monday. The company has a market cap of $530.89 million, a PE ratio of -44.90 and a beta of 1.52. The business’s 50 day moving average is $9.56 and its two-hundred day moving average is $9.61. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently modified their holdings of the business. Woodline Partners LP raised its holdings in shares of Zevra Therapeutics by 11.5% during the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after acquiring an additional 476,032 shares in the last quarter. Readystate Asset Management LP raised its stake in shares of Zevra Therapeutics by 924.6% during the 1st quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock worth $5,116,000 after purchasing an additional 616,370 shares in the last quarter. Retirement Planning Co of New England Inc. lifted its holdings in shares of Zevra Therapeutics by 6.9% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company’s stock valued at $4,121,000 after buying an additional 35,348 shares during the last quarter. Velan Capital Investment Management LP increased its stake in shares of Zevra Therapeutics by 121.7% during the 1st quarter. Velan Capital Investment Management LP now owns 665,000 shares of the company’s stock worth $4,981,000 after purchasing an additional 365,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Zevra Therapeutics by 2.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock valued at $1,148,000 after purchasing an additional 3,827 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Insider Activity at Zevra Therapeutics

In related news, Director John B. Bode acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, August 19th. The shares were acquired at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company’s stock, valued at $412,200. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Neil F. Mcfarlane sold 19,500 shares of the company’s stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the sale, the chief executive officer owned 222,016 shares of the company’s stock, valued at $2,402,213.12. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.40% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.